Navigation Links
Idenix Pharmaceuticals Prices Public Offering of Common Stock
Date:4/8/2011

CAMBRIDGE, Mass., April 8, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix. The offering is expected to close on April 13, 2011, subject to customary closing conditions.

J.P. Morgan Securities LLC is acting as sole book-running manager and underwriter for the offering. Idenix has granted the underwriter a 30-day option to purchase up to an additional 2,746,500 shares to cover over-allotments, if any.

The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. Idenix will also file with the Securities and Exchange Commission a prospectus supplement with respect to the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Idenix, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained, when available, from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
5. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
6. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
7. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... North America , ... The global market is expected to reach USD 20,190.1 Million by ... of 10.2%. --> North America , ... MarketsandMarkets, The global market is expected to reach USD 20,190.1 Million ... CAGR of 10.2%. --> According to a new market ...
(Date:2/11/2016)... , February 11, 2016 ... Market Report 2016 research report provides information on ... development status with crucial statistical data and information ... http://www.deepresearchreports.com/142870.html . --> Complete report on ... companies and supported with 296 tables and figures ...
(Date:2/10/2016)... , Feb. 11, 2016  QT Vascular Ltd., together ... and together with its subsidiaries, the "Group"), is ... litigation with AngioScore, Inc. ("ÄngioScore") (now owned by ... the United States Court ... Circuit") reversed an earlier district court order (the ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission ... for the Board of Commissioners. Individuals interested in volunteer board service are encouraged ... of clinical practice settings and across allied health to contribute to its mission ...
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD ... Counsel. Garrett will focus on contract negotiations, corporate strategy and healthcare data law. ... and best practices in data breaches for the Part D Star Rating improvement ...
(Date:2/11/2016)... Orange City, FL (PRWEB) , ... February 11, ... ... has announced the commencement of a master charity program created to assist the ... every 60 days, working closely with nonprofit organizations and community leaders. Their hope ...
(Date:2/11/2016)... ... 11, 2016 , ... AccuVein Inc. announces the Infusion Nurses ... Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ), ... market, facilitates adherence to this standard with its easy to use, widely deployed ...
(Date:2/11/2016)... TX (PRWEB) , ... February 11, 2016 , ... ... surrounding communities with their ongoing community involvement program, introduces a new charity campaign ... hospitalized children, donations are now being accepted at https://donate.rmhc.org/ . , Ronald ...
Breaking Medicine News(10 mins):